StockData
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc (JAZZ) stock

JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$247.77+7.06 (+2.93%)

Close on Nov 18, 2026Market cap $16.08BP/E 80.7Yield –

Jazz Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Jazz Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $4.72B, up 13.5% year over year. For fiscal 2025 it was $4.27B, up 4.9% from the year before. Over ten years it grew 12.4% a year on average. The highest annual figure on record is $4.27B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.27B+4.9%
FY2024Dec 31, 2024$4.07B+6.1%
FY2023Dec 31, 2023$3.83B+4.8%
FY2022Dec 31, 2022$3.66B+18.3%
FY2021Dec 31, 2021$3.09B+30.9%
FY2020Dec 31, 2020$2.36B+9.3%
FY2019Dec 31, 2019$2.16B+14.3%
FY2018Dec 31, 2018$1.89B+16.8%
FY2017Dec 31, 2017$1.62B+8.8%
FY2016Dec 31, 2016$1.49B+12.3%
FY2015Dec 31, 2015$1.32B+13.0%
FY2014Dec 31, 2014$1.17B+34.4%
FY2013Dec 31, 2013$872.42M+48.9%
FY2012Dec 31, 2012$585.98M+115.2%
FY2011Dec 31, 2011$272.28M+56.7%
FY2010Dec 31, 2010$173.78M+35.3%
FY2009Dec 31, 2009$128.45M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.24B+10.4%
Q2 FY2026Jun 30, 2026$1.21B+15.5%
Q1 FY2026Mar 31, 2026$1.07B+19.1%
Q4 FY2025Dec 31, 2025$1.20B+10.1%
Q3 FY2025Sep 30, 2025$1.13B+6.7%
Q2 FY2025Jun 30, 2025$1.05B+2.1%
Q1 FY2025Mar 31, 2025$897.80M-0.5%
Q4 FY2024Dec 31, 2024$1.09B+7.5%
Q3 FY2024Sep 30, 2024$1.05B+8.5%
Q2 FY2024Jun 30, 2024$1.02B+6.9%
Q1 FY2024Mar 31, 2024$901.98M+1.0%
Q4 FY2023Dec 31, 2023$1.01B+4.1%
Q3 FY2023Sep 30, 2023$972.14M+3.3%
Q2 FY2023Jun 30, 2023$957.32M+2.6%
Q1 FY2023Mar 31, 2023$892.81M+9.7%
Q4 FY2022Dec 31, 2022$972.12M+8.4%
Q3 FY2022Sep 30, 2022$940.65M+12.2%
Q2 FY2022Jun 30, 2022$932.88M+24.1%
Q1 FY2022Mar 31, 2022$813.72M+33.9%
Q4 FY2021Dec 31, 2021$896.73M+34.7%
Q3 FY2021Sep 30, 2021$838.12M+39.5%
Q2 FY2021Jun 30, 2021$751.81M+33.7%
Q1 FY2021Mar 31, 2021$607.58M+13.6%
Q4 FY2020Dec 31, 2020$665.52M+14.4%
Q3 FY2020Sep 30, 2020$600.89M+11.8%
Q2 FY2020Jun 30, 2020$562.44M+5.3%
Q1 FY2020Mar 31, 2020$534.73M+5.2%
Q4 FY2019Dec 31, 2019$581.74M+22.1%
Q3 FY2019Sep 30, 2019$537.70M+14.6%
Q2 FY2019Jun 30, 2019$534.13M+6.7%
Q1 FY2019Mar 31, 2019$508.19M+14.3%
Q4 FY2018Dec 31, 2018$476.46M+9.2%
Q3 FY2018Sep 30, 2018$469.37M+14.0%
Q2 FY2018Jun 30, 2018$500.48M+26.9%
Q1 FY2018Mar 31, 2018$444.61M+18.2%
Q4 FY2017Dec 31, 2017$436.40M+10.0%
Q3 FY2017Sep 30, 2017$411.86M–
Q2 FY2017Jun 30, 2017$394.39M–
Q1 FY2017Mar 31, 2017$376.05M–
Q4 FY2016Dec 31, 2016$396.62M–

More Jazz Pharmaceuticals figures

See a number that looks wrong?